The Federal Trade Commission (FTC) has intensified efforts to curb the trend of listing illegitimate drug patents. On September 14, the FTC issued a policy statement cautioning drug manufacturers against listing noncompliant drug patents within the U.S. Food and Drug Administration’s Orange Book. This move was unanimously voted upon and forms part of a recent initiative by the FTC aimed at stimulating competition, enhancing access to essential medicines, and alleviating the surge in pharmaceutical costs. For more details, please click here.
The Orange Book, whose formal title is Approved Drug Products With Therapeutic Equivalence Evaluations, is a crucial resource that assists health-care professionals and the industry in determining the patent and exclusivity status of FDA-approved drugs. The listing of noncompliant patents not only breaches the integrity of this resource but also hinders competition, potentially causing an unjustified rise in medication costs.
This strong stance by the FTC underlines the central role patent integrity plays in facilitating a dynamic and competitive market, which is vital in ensuring that affordable and essential drugs are readily available to consumers.